Hormone Replacement Therapy Market Segmentation:
Indication Segment Analysis
In the indication segment, the menopause segment is the dominant segment poised to hold the share of 43.6% in 2037. The menopause related hormone therapy dominates the market with the growing postmenopausal population, increasing longevity and rising hormonal imbalance symptoms. As per the National Institute on Aging, nearly 1.5 billion women will experience postmenopausal by 2030, which increases the demand for combination HRT therapies and demand for estrogen. Furthermore, the Women's Health Initiative (WHI) from NIH reports that structured guidelines on the HRT safety, boosts the patient compliance and physician recommendations.
Therapy Type Segment Analysis
In the therapy type segment, the estrogen sub segment leads the market and expected to hold the market share 38.4% by 2037. The estrogen monotherapy fuels the segment based on the women who have undergone hysterectomy. As per the report from U.S. Food & Drug Administration many low dose estrogen components have safety profiles. The Office on Women’s Health highlights the therapeutic advantages of customized estrogen HRT for postmenopausal treatment.
Our in-depth analysis of the global market includes the following segments:
|
Segment |
Subsegment |
|
Indication |
|
|
Therapy Type |
|
|
End user |
|
